rs4646976 — CYP2E1

CYP2E1 intronic haplotype tag — affects enzyme activity and susceptibility to drug-induced liver injury and chemical toxicity

See your personal result for CYP2E1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP2E1 — Gatekeeper for Chemical Toxicity

CYP2E1 is one of the most toxicologically consequential enzymes in the human liver. While it metabolizes only a small fraction of common drugs, it handles a disproportionate share of industrial chemicals, environmental carcinogens, solvents, and the reactive pathway for acetaminophen overdose. The rs4646976 variant in intron 6 of CYP2E1 is a haplotype tag — a marker that travels together with functional variants that alter the enzyme's activity level, shaping an individual's susceptibility to drug-induced liver injury, chemical carcinogenesis, and alcohol-mediated hepatotoxicity.

The Mechanism

CYP2E1 is expressed primarily in hepatocytes and catalyzes the oxidative metabolism of small, lipophilic molecules including ethanol11 ethanol
The primary mechanism by which drinking alcohol damages the liver, acetaminophen (paracetamol), halothane, isoflurane, benzene, carbon tetrachloride, chloroform, and the food contaminant acrylamide. Its most clinically significant reaction is the conversion of acetaminophen to NAPQI22 NAPQI
N-acetyl-p-benzoquinone imine — a highly reactive electrophile that depletes hepatic glutathione and binds covalently to liver proteins, causing cell death. At therapeutic doses, glutathione neutralizes NAPQI before it can cause damage; when CYP2E1 activity is elevated or glutathione stores are depleted (by fasting, alcohol use, or malnutrition), even standard doses can trigger hepatocellular injury.

rs4646976 (NM_000773.4:c.967+326A>G) is located in intron 6 of CYP2E1 and was catalogued as a key haplotype-tagging marker in a global study of 11 CYP2E1 polymorphisms33 CYP2E1 polymorphisms
Lee et al. Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene. Pharmacogenomics J, 2008 across 2,600 individuals from 50 world populations. The G allele is present at approximately 18% frequency in East Asian populations but only ~1% in Europeans, making it a population-differentiated marker of CYP2E1 haplotype diversity.

The Evidence

The clinical significance of CYP2E1 variation rests on three well-documented bodies of evidence:

Acetaminophen hepatotoxicity. Lee et al. (1996)44 Lee et al. (1996)
Lee SS et al. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem, 1996 established CYP2E1 as the principal enzyme converting acetaminophen to NAPQI using knockout mice, which were dramatically resistant to acetaminophen's hepatotoxic effects. CYP2E1 is strongly induced by ethanol, fasting, obesity, and diabetes, which explains why these conditions multiply acetaminophen hepatotoxicity risk even at recommended doses.

Anti-tuberculosis drug-induced liver injury. Huang et al. (2003)55 Huang et al. (2003)
Huang YS et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003 showed that the high-activity CYP2E1 c1/c1 genotype conferred a 2.5-fold increased risk of hepatotoxicity during isoniazid treatment (OR 2.52) compared to c2 carriers. This is a clinically relevant finding because tuberculosis patients often have additional risk factors (malnutrition, alcohol use) that further sensitize them to CYP2E1-mediated isoniazid bioactivation.

Cancer susceptibility. A meta-analysis by Wang et al. (2010)66 Wang et al. (2010)
Wang Y et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer, 2010 covering 26 studies (4,436 cases, 6,385 controls) found that carriers of the c2 (lower-activity) allele had an 18% reduced risk of lung cancer (OR 0.82, 95% CI 0.72–0.93), with stronger effects in Asian populations. The mechanism is CYP2E1's role in bioactivating benzene, tobacco-derived nitrosamines, and other inhaled procarcinogens into their DNA-damaging forms.

Practical Actions

Individuals carrying the G allele of rs4646976, which tags a CYP2E1 haplotype associated with reduced enzyme activity, have lower baseline capacity to generate NAPQI from acetaminophen. This is generally protective under normal circumstances but does not eliminate risk with high doses or when combined with inducers. Conversely, A/A individuals (the common, higher-activity genotype) have greater risk of dose-dependent acetaminophen toxicity — particularly when fasting, consuming alcohol, or taking drugs that induce CYP2E1.

Because CYP2E1 also activates benzene, chloroform, carbon tetrachloride, and industrial solvents into reactive metabolites, occupational or environmental exposures are particularly relevant for those with high-activity genotypes. In isoniazid-based tuberculosis therapy, CYP2E1 genotype has emerged as a useful predictor of hepatotoxicity risk when considered alongside NAT2 acetylator status.

Interactions

The most clinically significant interaction is with rs671 (ALDH2 Glu504Lys), common in East Asians, which impairs acetaldehyde clearance. Individuals carrying both high CYP2E1 activity (AA at rs4646976) and ALDH2 deficiency experience compounded alcohol-derived liver injury: CYP2E1 generates reactive oxygen species during ethanol oxidation while ALDH2 deficiency allows acetaldehyde to accumulate. A second relevant interaction involves NAT2 slow acetylator status (rs1799929, rs1799930, rs1208): individuals with both CYP2E1 c1/c1 and NAT2 slow acetylator status face a synergistic 6- to 7-fold increased risk of isoniazid-induced hepatotoxicity compared to fast NAT2 acetylators without high-activity CYP2E1.

Drug Interactions

acetaminophen increased_toxicity literature
isoniazid increased_toxicity literature
halothane increased_toxicity literature
enflurane increased_toxicity literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard Metabolizer Normal

Standard CYP2E1 activity

You carry two copies of the common A allele at rs4646976, consistent with the standard high-activity CYP2E1 haplotype. This is the most common genotype globally — about 84% of the global population carries this pattern, though it is almost universal (>96%) in Europeans.

Your CYP2E1 converts acetaminophen, ethanol, benzene, and environmental chemicals at the typical rate. Standard safe-dosing guidelines for acetaminophen (≤3,000 mg/day as a conservative ceiling, lower with alcohol use) apply to you. Alcohol use, fasting, and obesity can substantially induce your CYP2E1 activity above baseline, amplifying risk during those states.

AG Intermediate Activity Intermediate

One copy of the reduced-activity haplotype

You carry one copy of the G allele at rs4646976, which tags a CYP2E1 haplotype associated with moderately reduced enzyme activity. Heterozygotes have intermediate CYP2E1 activity — lower than A/A individuals but not as reduced as G/G. This genotype occurs at roughly 8% frequency globally and is proportionally more common in East Asian (~29%), South Asian (~14%), and African (~11%) populations.

Your reduced CYP2E1 activity means somewhat less NAPQI generation from acetaminophen, a modestly lower activation of environmental procarcinogens, and potentially lower risk of CYP2E1-mediated drug-induced liver injury compared to A/A individuals. The effect at the heterozygous level is moderate rather than dramatic.

GG Reduced Activity Reduced

Reduced CYP2E1 enzyme activity

The c2-type CYP2E1 haplotype (tagged by the G allele at rs4646976 and linked intronic/promoter variants) has been associated with lower enzyme activity in multiple studies. Meta-analyses show that c2 carriers have a reduced risk of anti-tuberculosis drug-induced hepatotoxicity compared to c1/c1 individuals, who have the highest enzyme activity and the greatest hepatotoxin production from isoniazid. For lung cancer, a meta-analysis of 26 studies (Wang et al. 2010) found c2 carrier status associated with OR 0.82 for lung cancer risk, driven largely by reduced bioactivation of tobacco-associated carcinogens.

Importantly, reduced CYP2E1 activity does not offer strong protection at supratherapeutic acetaminophen doses — CYP3A4 takes over at high doses, and NAPQI generation still occurs. The protective effect is most relevant at therapeutic doses in the context of CYP2E1-inducing states (alcohol consumption, fasting, obesity).